VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year

Deep News

Oct 06

VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.

According to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.

In June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1188705635"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188705635\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188705635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188705635","market":"sg","top_or_hot":-1,"title":"VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year","media":"Deep News","content":"<p>VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.</p>\n<p>According to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.</p>\n<p>In June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-06 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.</p>\n<p>According to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.</p>\n<p>In June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维升药业-B","start_time":0,"source_url":"","article_id":"1188705635","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188705635","pubTimestamp":1759722636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million. According to VISEN PHARMA's prospectus, the company's most...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B","BK1161":"生物科技"},"translate_title":"由于长效生长激素等待今年批准，VISEN PHARMA-B早盘飙升逾3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.\nAccording to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.\nIn June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}